Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of KoreaGlobeNewsWire • 02/02/23
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation's Spring Clinical MeetingsGlobeNewsWire • 01/23/23
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023GlobeNewsWire • 01/05/23
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common StockGlobeNewsWire • 12/29/22
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of RenazorbGlobeNewsWire • 12/28/22
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United KingdomGlobeNewsWire • 12/22/22
Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)Accesswire • 12/09/22
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic AtrophyGlobeNewsWire • 11/21/22
Unicycive Announces Third Quarter Financial Results and Provides Business UpdateGlobeNewsWire • 11/14/22
Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology's Kidney Week 2022GlobeNewsWire • 10/26/22
Unicycive Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/06/22
Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology's Kidney Week 2022GlobeNewsWire • 08/24/22
Unicycive Announces Second Quarter Financial Results and Provides Business UpdateGlobeNewsWire • 08/15/22
Traders News Source Interviews Dr. Shalabh Gupta, CEO at Unicycive Therapeutics, Inc.Accesswire • 05/24/22
Glancy Prongay & Murray LLP Announces Investigation of Unicycive Therapeutics, Inc.Business Wire • 04/14/22
Unicycive Announces Key Opinion Leader Event Highlighting Novel Treatments in Kidney DiseasesGlobeNewsWire • 04/14/22
Unicycive Announces Full Year 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 03/31/22
Unicycive Announces Renazorb Pre-clinical and Clinical Data Selected for Presentation at National Kidney Foundation Spring Clinical MeetingPRNewsWire • 02/02/22
Unicycive Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual ConferencePRNewsWire • 01/10/22